EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Cytomegalovirus reactivation in mechanically ventilated patients with or without SARS-CoV-2 infection: A retrospective cohort study

Octave Cannac, Vanessa Pauly, Christine Zandotti, Léa Luciani, Paul-Rémi Petit, Xavier de Lamballerie, Rémi Charrel, Laurent Papazian, Damien Barrau iD, Geoffray Agard iD, Sami Hraiech iD

PLOS One · 2025

DOI: 10.1371/journal.pone.0328494 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift PLOS One, 2025. Verfasst von Octave Cannac und 10 weiteren Autor:innen. Beteiligte Einrichtung: Service de Médecine Intensive Réanimation, APHM, Hôpital Nord, Marseille, France. Hauptthemen laut MEDLINE: COVID-19, Respiration, Artificial, Cytomegalovirus, Cytomegalovirus Infections. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Data comparing the incidence, risk factors and outcomes of cytomegalovirus (CMV) reactivation in SARS-CoV-2 positive and negative patients remain controversial.

Design

A retrospective cohort study in a tertiary center. Patients Patients admitted to the intensive care unit between December 2019 and May 2021, under invasive mechanical ventilation for 4 days or more and screened for CMV reactivation were included.

Measurements

The primary outcome was the incidence of CMV reactivation in SARS-CoV-2 negative and positive patients. Secondary outcomes included risk factors for CMV reactivation in both populations and survival analysis according to CMV reactivation in SARS-CoV-2 negative and positive patients.

Results

CMV reactivation occurred in 34.7% (n = 51/147) of SARS-CoV-2 negative patients and in 45.4% (83/183) of SARS-CoV-2 positive patients ( p = 0.08). When considering competing factors, SARS-CoV-2 infection was not associated with CMV reactivation (sub-hazard ratio (SHR) = 1.01 [0.68–1.49], p = 0.98). Treatment with methylprednisolone was significantly associated with CMV reactivation in the unadjusted and adjusted analysis (SHR 2.81 [2.01–3.93] p < 0.001; SHR 2.84 [1.94–4.15] p < 0.001 respectively). Patients combining SARS-CoV-2 infection and CMV reactivation had a significantly higher all-cause mortality. Among patients presenting a CMV reactivation, the administration of ganciclovir was a protective factor for day-60 mortality (HR = 0.4; [0.22–0.74] p = 0.004).

Conclusion

In this large retrospective cohort, CMV reactivation was not significantly associated with SARS-CoV-2 infection in patients undergoing invasive mechanical ventilation for at least 4 days. The major risk factor for CMV reactivation was treatment with methylprednisolone. The combination of CMV reactivation with SARS-CoV-2 infection was associated with a higher mortality whereas ganciclovir treatment reduced mortality.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Respiration, ArtificialCytomegalovirusCytomegalovirus InfectionsVirus ActivationHumansMaleFemaleRetrospective StudiesMiddle AgedAgedSARS-CoV-2Risk FactorsMethylprednisoloneIntensive Care Units

Substanzen

Methylprednisolone

Autor:innen und Institutionen

  • Service de Médecine Intensive Réanimation, APHM, Hôpital Nord, Marseille, France.
  • Aix Marseille University, School of Medicine - La Timone Medical Campus, EA 3279, CEReSS - Health Services Research and Quality of life Center, Marseille, France.
  • Unité des Virus Émergents (UVE), Aix-Marseille Univ-IRD 190-Inserm 1207, Marseille, France.
  • Laboratoire BVH -Virologie - Aigue - Tropique- AP-HM, Marseille, France.
  • Le Service de Prévention du Risque Infectieux (LESPRI), CLIN AP-HM Hôpitaux Universitaires de Marseille, Marseille, France.
  • Laboratoire des Infections Virales Aigues et Tropicales, Pole des Maladies Infectieuses, AP-HM Hôpitaux Universitaires de Marseille, Marseille, France.

ORCID-Profile: Damien Barrau, Geoffray Agard, Sami Hraiech

Zitieren

APA

Cannac, O., Pauly, V., Zandotti, C., Luciani, L., Petit, P. R., de Lamballerie, X., Charrel, R., Papazian, L., Barrau, D., Agard, G., & Hraiech, S. (2025). Cytomegalovirus reactivation in mechanically ventilated patients with or without SARS-CoV-2 infection: A retrospective cohort study. PLOS One. https://doi.org/10.1371/journal.pone.0328494

Vancouver

Cannac O, Pauly V, Zandotti C, Luciani L, Petit PR, de Lamballerie X, et al. Cytomegalovirus reactivation in mechanically ventilated patients with or without SARS-CoV-2 infection: A retrospective cohort study. PLOS One. 2025. doi:10.1371/journal.pone.0328494

BibTeX
@article{Cannac2025,
  author = {Cannac, Octave and Pauly, Vanessa and Zandotti, Christine and Luciani, Léa and Petit, Paul-Rémi and de Lamballerie, Xavier and Charrel, Rémi and Papazian, Laurent and Barrau, Damien and Agard, Geoffray and Hraiech, Sami},
  title = {Cytomegalovirus reactivation in mechanically ventilated patients with or without SARS-CoV-2 infection: A retrospective cohort study},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0328494}
}
Kostenlos starten →